01:17 , Jun 21, 2019 |  BC Innovations  |  Finance

What Australian biotech needs to compete globally

Australia aims to be more than a destination for clinical trials, and an influx of cash is helping the country’s biotech sector fill its translational gap. But like other emerging biotech hubs, talent and a...
21:36 , Jun 3, 2019 |  BC Extra  |  Company News

Management tracks: Zai, Jazz, PTC, BIO and more

Cancer company Zai Lab Ltd. (NASDAQ:ZLAB) hired Valeria Fantin as its first CSO. She was CSO of Oric Pharmaceuticals Inc. (South San Francisco, Calif.). Cancer and neurology company Jazz Pharmaceuticals plc (NASDAQ:JAZZ) hired Robert Iannone...
22:59 , May 23, 2019 |  BC Extra  |  Politics & Policy

Draft bill on patent eligibility could revitalize diagnostics

A bipartisan, bicameral draft bill released on Wednesday would solve a key problem with patent law that has crippled the diagnostics industry, but opposition from other industries is likely. The draft bill was released by...
21:37 , Feb 14, 2019 |  BC Extra  |  Politics & Policy

Changing SOX? Senate bill would extend biotech exemption

A bipartisan group of Senators reintroduced legislation that would extend an exemption for pre-revenue biotechs from compliance with certain accounting rules under Sarbanes-Oxley. Sens. Thom Tillis (R-N.C.), Kyrsten Sinema (D-Ariz.), Gary Peters (D-Mich.) and David...
21:53 , Oct 11, 2018 |  BC Extra  |  Politics & Policy

Inter Partes Review to be more favorable to biotech

The U.S. Patent and Trademark Office (PTO) finalized a rule requiring higher standards for invalidating patents through inter partes review (IPR) petitions, a victory for biopharma companies and other industries that depend on strong patent...
20:05 , Jul 25, 2018 |  BC Extra  |  Politics & Policy

BIO pushes Congress for JOBS Act relief

GlycoMimetics Inc. (NASDAQ:GLYC) CEO Rachel King urged Congress Wednesday to relax rules for public biotech companies not yet making a profit and build on earlier legislation through the proposed JOBS and Investor Confidence Act of...
00:03 , May 19, 2018 |  BioCentury  |  Politics, Policy & Law

Shifting parts

HHS Secretary Alex Azar is convinced that the way Medicare Part B spends money for drugs makes no sense, costs the taxpayers too much and isn’t good for patients. He says he’s open to suggestions...
21:43 , May 8, 2018 |  BC Extra  |  Politics & Policy

PTO leveling IPR playing field

The U.S. Patent and Trademark Office (PTO) wants to level the playing field between patent challenges filed as inter partes review (IPR) petitions and those considered by federal courts. If finalized, the policy would represent...
00:48 , Feb 10, 2018 |  BioCentury  |  Politics, Policy & Law

Money in your pocket

Under intense pressure from President Donald Trump to take steps that visibly lower the cost of drugs, HHS Secretary Alex Azar is reaching for low-hanging fruit. The administration’s proposed budget, which will be released on...
02:21 , Jan 5, 2016 |  BC Extra  |  Politics & Policy

BIO changes name

The Biotechnology Industry Organization changed its name to the Biotechnology Innovation Organization. The group, which announced plans in June to change its name, intends to continue using the "BIO" acronym....